Male gender (hazard ratio [HR] 4.0 95% confidence interval [CI] 1.4-11.2, P = 0.008) and severity of TBI (HR 1.3 95% CI 1.1-1.4, P < 0.001 for each 10% increase in risk of poor 6 month outcome) predicted time to AKI. KDIGO stage 1 (HR 8.8 95% CI 4.5-17, P < 0.001), KDIGO stage 2 (HR 13.2 95% CI 3.9-45.2, P < 0.001) and KDIGO stage 3 (HR 11.7 95% CI 3.5-39.7, P < 0.005) predicted time to mortality. EPO did not influence time to AKI (HR 1.08 95% CI 0.7-1.67, P = 0.73) or creatinine levels during ICU stay (P = 0.09).
Conclusions: Acute kidney injury is more common in male patients and those with severe compared to moderate TBI and appears associated with worse outcome.
EPO does not prevent AKI after TBI.
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| INTRODUCTION

Traumatic brain injury (TBI) is a rising global health concern affecting
especially the younger population and results in both high mortality and, in many cases, lifelong morbidity and considerable treatment costs. [1] [2] [3] Severely injured TBI patients require treatment in an intensive care unit (ICU). 4 During ICU care, TBI patients are at risk of developing complications such as various degrees of organ failure. 5 One serious complication is acute kidney injury (AKI), which has been shown to occur in 18%-36% of trauma patients treated in the ICU. 6, 7 Severity of AKI may range from a momentary decrease in urinary output or a slight increase in a creatinine, to complete anuria and the need for renal replacement therapy. 7 Recombinant erythropoietin (EPO) has been shown to have renal protective effects in experimental studies. [8] [9] [10] The use EPO for prevention of AKI has been studied in patients undergoing cardiac surgery and following renal transplantation, but thus far the data are conflicting. [11] [12] [13] [14] No studies have assessed the effect of EPO on kidney function in patients with trauma. 15 Accordingly, we aimed to assess the incidence and factors increasing the likelihood as well as survival association of AKI in patients with moderate to severe TBI.
Secondarily, we studied the effect of EPO on kidney function by comparing the occurrence of AKI using the Kidney Disease Improving Global Outcome (KDIGO) classification and creatinine levels in patients treated with either EPO or placebo.
| ME TH ODS
The EPO-TBI study was an international randomized controlled trial conducted in multiple centers in Australia, New Zealand, Saudi Arabia, France, Finland, Ireland and Germany between 3 May 2010 and 1 November 2014. 16 All patients treated in the ICU for moderate or severe TBI were screened for eligibility ( Figure S1 ). Patients with end-stage renal failure receiving chronic dialysis were excluded from the trial. Enrolled patients received either weekly doses of 40 000 IU of subcutaneous epoetin alfa (Eprex Janssen-Cilag Pty Ltd, Titusville, NJ, USA) or placebo (0.9% sodium chloride). The randomization process and administration of drug has been described previously. 15 The administration of EPO continued until patients had received a maximum of three doses, or until the patients was discharged from the ICU. 17, 18 A consort checklist for the reporting of this study is included in the Supplemantary Materials. The EPO-AKI sub-study was a pre-planned study and the protocol (a part of the original EPO-AKI protocol) is included in the Supplementary Materials.
| Data collection
A web-based case record form was used including detailed data on patient characteristics, injury mechanism, pre-hospital care and immediate hospital management. 17 
| Study outcomes
The primary outcome of this study was the presence and timing of KDIGO stages 1-3 based on creatinine levels during the whole ICU stay. A secondary outcome was KDIGO stages 1-3 based on creatinine levels and urinary output during the first 7 days. Patient outcomes included ICU, hospital and 6-month survival. Neurological function at 6 months was determined by an assessor blinded to treatment group using the Glasgow Outcome Scale extended (GOSE). The GOSE ranges from 1-8 with good outcome defined as a GOSE score of 5-8.
| Sample size analysis
Prior to the study initiation it was estimated that the incidence of AKI (KDIGO 1-3 compared to no KDIGO class) would be around 9%. Given this assessment, a trial with 287 patients in each group was estimated to have an 86% power to detect a change from 9% to 3% with a two sided P-value 0.05. The EPO-TBI trial enrolled 602 patients.
| Statistical analysis
Categorical data are presented as counts and percentages and are compared using chi-square test. Numerical data are presented as medians and interquartile range (IQR) in parenthesis. 
| Admission risk factors for AKI
There were several differences in both patient, injury and treatment characteristics between patients that developed and those who did not develop AKI during ICU stay (Table S1) . Notably, patients with AKI were more commonly of male gender; had a higher body weight and more severe brain injury (Table S1 ). On
Cox regression analysis, independent predictors of time to development of AKI were male gender (HR 4.0 95% CI 1.4-11.2, P = 0.008), and severity of TBI according to the IMPACT model (per 10% increase in risk of poor outcome, HR 1.25 95% CI 1.1-1.4, P < 0.001; Table 1 ).
| Risk factors for AKI on day 3
In a COX regression model for time to AKI later than day 3, excluding those who had died or developed AKI before day 3, several CI 0.6-1.5, P = 0.70) (Table S2 ).
| Association of AKI with outcome
Patients with AKI (any KDIGO stage 1-3 during their ICU stay) had a higher ICU mortality (32% compared to 6%, P < 0.001), hospital mortality (33% compared to 8%, P < 0.001) and 6-month mortality (34% compared to 10%, P < 0.001; Table S3 ). Prior to day 3, 26 patients had died and nine patients had developed AKI. Survival Table S3 ). Similar findings were seen in patients with AKI occurring during the first 7 days (Table S4 ). Good neurologic recovery defined according to the GOSE scale occurred in 31 (38%) of 82 AKI patients compared to 299 (58%) of 514 non-AKI patients (P < 0.001).
In a Cox regression model including KDIGO class as a timedependent covariate, all three KDIGO stages were related to 6-month mortality (Table 2 ). Other significant predictors of increased mortality were age (HR 1.04 95% CI 1.02-1.05, P < 0.001), abnormal pupils (HR 2.0 95% CI 1.2-3.3, P = 0.01) while treatment with EPO (HR 0.61 95% CI 0.38-0.96, P = 0.03) predicted decreased mortality.
Similar findings were seen using AKI occurring during the first 7 days (Table S5) . 
| Effect of EPO on AKI
| DISCUSSION
We studied the EPO-TBI trial population to assess the incidence and outcome associations of AKI in patients with TBI admitted to ICU.
Moreover, we aimed to test whether EPO treatment was associated with any evidence of a renal protective effect. We found that AKI as defined by the KDIGO criteria based on creatinine levels occurred in one in seven patients. AKI based on either urinary output or creatinine levels during the first 7 days was more common and occurred in 40% of patients. All forms of AKI had an independent association with long-term mortality, but the CIs were wide. Finally, the use of EPO did not provide any protection from AKI.
The incidence of AKI was comparable to previous studies con- reported an AKI incidence rate of 18% during the first 24 hours.
Gomes et al 22 observed AKI in 50% of trauma patients admitted to the ICU. Noteworthy is that this study, due to its design, excluded some categories of patients in whom AKI might be even more common.
All stages of AKI were associated with a marked increase in mortality compared to patients without AKI. Previous studies including patients with all types of trauma, have shown similar findings, but data in patients with TBI have are limited. 6, 7, 23, 24 One possible mechanism for the increase in mortality in TBI is aggravated cerebral edema due to changes in osmolality. 26 In a recent study, Siew et al 26 showed that among ICU patients with shock and respiratory failure, KDIGO stage 2 and 3 are significant risk factors for both delirium and coma. Interestingly, the use of RRT has been shown to be associated with a very high mortality after TBI. 26 This was not the case in this study, as all but one of eight patients that received RRT survived.
This study identified several known markers of increased risk of AKI including male gender. This observation may be explained by F I G U R E 2 Survival curves in 599 (excluding deaths prior to day 3) traumatic brain injury patients treated in the intensive care unit indexed by the development of acute kidney injury before day 3 based on creatinine and urinary output [Colour figure can be viewed at wileyonlinelibrary.com] differences in weight and muscle mass between males and females:
a greater increase in creatinine in males may occur without a true decrease in renal function. This study also suggested an association between the use of therapeutic hypothermia (TH) and increased likelihood of AKI. It is possible that vasoconstriction, induced by hypothermia, reduces renal blood flow. 27 A meta-analysis including mainly patients resuscitated from cardiac arrest suggested no difference in the prevalence of AKI in between TH and normothermia. 28 On the other hand in a sub-study from the Hypothermia and Cardiac
Arrest trial, the use of hypothermia was associated with a delay in renal recovery. 29 The study on the use of early induction of TH in TBI by Clifton et al 30 showed no difference in creatinine levels between groups but did show an increased use of intravenous fluids with TH.
Despite multiple animal studies suggesting positive effects on the kidney, we did not find that EPO protected patients from AKI. 31 The use of EPO in animal models has been shown to decrease the extent of ischemia reperfusion injury, reduce the incidence of contrast induced nephropathy and alleviate inflammation. [8] [9] [10] 32 The proposed protective mechanisms include reduction in apoptotic cell T A B L E 2 Independent predictors of mortality in patients included in the erythropoietin (EPO) in traumatic brain injury (TBI) trial including time to development and severity of acute kidney injury The reference category is no AKI (Absence of KDIGO 1-3).
F I G U R E 3
The timing and cumulative cases of acute kidney in injury in patients treated with erythropoietin (EPO) or placebo in the EPO in traumatic brain injury trial [Colour figure can be viewed at wileyonlinelibrary.com] death by several mechanisms. 33, 34 In the ischemic kindey EPO enhances tissue regeneration, and neovascularization. 35, 36 EPO also suppresses the synthesis of TNF-alpha and interleukin-2 inflammatory markers which may part in the development of AKI. 34 In smaller clinical trials, EPO has been shown to alleviate early AKI after coronary artery bypass grafting. 37 Thus, in trauma patients EPO could the expected to have some protective effects within 24-48 hours after injury. Despite experimental and evidence, a lack in positive effects on renal function has been shown in patients undergoing kidney transplantation and in this study, in TBI patients with trauma. 15 It needs to be noted that the renal endpoints we studied, that is, KDIGO although relevant, may be too crude to detect smaller changes in renal function. All in all our finding corroborate that human AKI is much more complex than in experimental AKI.
| Study strengths and limitations
This study has a number of strengths. Centres from different health systems participated and therefore our results are likely to be generalizable. We also had detailed data on severity of TBI and were able to adjust for that in the analysis.
Nonetheless several limitations need to be kept in mind. The study did not include data specific medical conditions such as hypertension, diabetes mellitus or chronic kidney disease that may influence the development of AKI. In addition, the study did not include data on the use of medications, maintenance fluids, myoglobin levels, or therapies that might have influenced renal function. We only had data on urinary output during the first 7 days. The UO data only included whether any of the KDIGO UO criteria occurred during the first 7 days and did not include hourly or total diuresis. The study only includes short-term data on kidney function and thus we cannot comment of long-term effects of EPO on kidney function. Finally, as the main sample size calculation was based on an assumed change in neurologically intact survivors at 6 months between the EPO and placebo groups, this sub-study may be underpowered to detect clinically meaningful differences the more severe forms of AKI such as the need for RRT in TBI patients.
| CONCLUSION
Within this RCT including patients with moderate to severe TBI, AKI was independently associated with mortality. We identified several factors associated with increasing the risk of AKI including increasing patient weight, male gender, more severe TBI, more severe admission illness severity, and the use of therapeutic hypothermia. Contrary to our hypothesis and despite compelling animal evidence, the use of EPO did not attenuate renal injury in this population.
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